2022 Global Cannabis Market Overview
The “The Global Cannabis Report: Second Edition Including Market Sizing Data & Real-World Data” report has been added to ResearchAndMarkets.com’s offering.
After a tough year for cannabis in 2020, 2021 brought along a rebound in development towards legalisation, record-breaking sales of medical and adult-use cannabis as well as a massive influx of capital raises and M&A activity.
This report finds combined global sales of CBD, medical and adult-use cannabis topped US$37.4 billion in 2021, and could rise to US$105 billion by 2026
Overall, the industry is poised for a very exciting 2022, with the spread of legalisation being followed by strong industry growth. Benefits will be felt across justice, public health and the global economy.
This report provides an overview of the key developments in international cannabis markets, and considers how they might develop in the near future. It also covers some of the most interesting and pertinent global trends in the industry.
The market sizing data package available provides country-level breakdowns of market sizing forecasts (2021-2026) for global cannabis markets, including medical, adult-use and CBD.
In addition, this package comes complete with the most comprehensive collection of real-world data available anywhere in the world: official data obtained from governments and health authorities globally, providing state/country-level metrics such as patient numbers, product source, and sales by product format.
Cannabis Market Overview
Adult-use markets in the US and Canada remain the most important regions in the world for cannabis sales, but international markets including Germany, Israel and Australia will develop considerably over the next five years.
While the COVID-19 lockdown period saw record-breaking sales of cannabis in multiple regions, legislative developments have been interrupted, bringing delays in the development of cannabis market value across the globe.
As of late 2021 only Uruguay, Canada and a handful of states in the US have fully legalised cannabis for adult-use, but these will be joined by several international markets soon.
Mexico is primed for full legalisation of adult-use cannabis in 2022, while the Netherlands and Switzerland are preparing for their legal pilot trials. In November 2021, the coalition of parties set to lead the next German Government released a statement confirming that they have agreed to legalise the use and sales of adult-use cannabis in the country. This could signal the beginning of the largest cannabis industry outside of North America.
Medical cannabis and CBD are now legal, in some form, across most of North America, the European Union (EU) and the United Kingdom (UK), as well as Latin America; with Africa and Asia-Pacific lagging behind.
In December 2020, the United Nations (UN) recognised the potential medical utility and the safety of cannabis implicitly by removing it from Schedule IV of the Single Convention on Narcotic Drugs.
The large US multi-state-operators now rival the Canadian players for their size, and for the most part, exceed them in immediate financial performance.
This year, 2021, has been a significant one for cannabis Mergers and Acquisitions (M&A) for example; the acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals for US$7.2 billion on 2 May, the merging of Aphria and Tilray, and the recent acquisition of Harvest Health and Recreation by Trulieve for US$ 2.2 billion.
Investor sentiment was shaken during the lockdown of 2020, and while stock prices are down, capital raises are now on the rise once again.
The balance of cannabis production is shifting away from the traditional strongholds of Canada and the Netherlands, with exports coming online from regions with warmer climates, cheaper land and labour; such as Latin America, the Mediterranean and Africa.
The most important import markets, including Germany and Israel, are currently engaging in domestic cultivation but it is yet to be seen how much future demand will be covered by this.
Ancillary services such as technology, professional services, extraction, distribution, packaging and construction are becoming increasingly important, with multi-billion dollar valuations for several cannabis technology companies.
Key Topics Covered:
- Definition and Scope
- Contents Overview
- Key Global Trends
- Medical Cannabis In A Rec-Legal World
- Medical Cannabis Supply Chain
- Cannabis Markets In A Post-Covid World
- Cannabis Stocks
- Market Sizing
- Regional Overviews
- Expert Interviews
- Always Pure Organics
- Canopy Growth
- Cresco Labs
- GW Pharmaceuticals
- Jazz Pharmaceuticals
- Linnea SA
- Village Farms
- White Lion Holdings
For more information about this report visit https://www.researchandmarkets.com/r/ulrw7d
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
2022 Global Cannabis Market Overview
About Cannin: Your Cannabis Stocks Resource
78% of Cannin’s fundamentals prove true within 30 days or less on 100+ recommendations over the past 2 years.
Cannin is your #1 trusted resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. In fact, we aggregate hundreds of hours of financial research and provide tips on the best cannabis stocks for 2021.
Use Cannin as your resource for:
Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.
Are you looking to buy stock in hemp companies or marijuana companies for 2021? If so, are you interested in new penny hemp stock companies? Or, looking for the best Canadian cannabis stocks to invest in? Maybe, you’re looking to leverage the power of algorithmic stock trading to beat the cannabis market? We can help.
Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.
- +34% Gains in 2022
- +56% Gains in 2021
- +30% Gains in 2020
- +49.8% Gains in 2019
- Backtested since 2012
In fact, we’re so confident you’ll love our algotrading cannabis stock signals, we’re willing to give you a one week risk-free trial to see it for yourself.
Profit from the best cannabis stocks – we’ll show you how at cannin.com.